Thomas Niel

Thomas Niel

InvestorPlace Contributor

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

5 High-Yield MLPs Worth a Look This Fall

By Thomas Niel, InvestorPlace Contributor

It may not be for several years energy stocks retrace their pre-pandemic price levels. But, with high-yields while you wait, and the opportunity for long-term upside, consider these five MLPs as we enter the fall.

Scant Vaccine Hopes Aren’t Enough to Make iBio a Buy

By Thomas Niel, InvestorPlace Contributor

As I detailed earlier this month, there are many pandemic vaccine plays out there with greater chances of success. That's not to say these rival candidates will find success. But, compared to IBIO stock, they look like worthwhile wagers.

Nio Stock May Be Crushing It, But It’s Time to Sell

By Thomas Niel, InvestorPlace Contributor

So, what's the play here? If you bought in at lower prices, it may be time to cash out. And if you missed the boat a few month's back? Don't try to play catchup by entering a position today, as shares remain "priced for perfection."

Novavax Stock Definitely Is Not the Long-Shot Vaccine Play You Might Think

By Thomas Niel, InvestorPlace Contributor

Bottom line: don't bet the ranch, but NVAX stock is a buy as it enters Phase 3 trials.

Jumia Stock Is Worth a Look, But Tread Carefully

By Thomas Niel, InvestorPlace Contributor

That being said, after the August sell-off, the odds may be more in your favor now than before with long-shot JMIA stock. Don't bet the ranch, but there's still opportunity here.

As Remote Work Becomes the Norm, Slack Remains Solid

By Thomas Niel, InvestorPlace Contributor

Despite the recent pullback in Slack stock, the shift to remote work is here to stay even after the coronavirus pandemic comes to an end.

Bull Case Isn’t Broken For Nokia Stock, But Tread Carefully

By Thomas Niel, InvestorPlace Contributor

The comeback story remains in play, but Nokia stock could keep heading lower in the near term. Wait for lower prices.

All Bets Are off for Workhorse Stock Despite This Current Enthusiasm

By Thomas Niel, InvestorPlace Contributor

What does that mean for investors? If you bought WKHS stock at lower prices, let it ride, as shares could continue to climb. But, if you have yet to enter a position, it may pay to take a "wait and see" approach.

Landcadia Stock Is Not DraftKings, So Sell Into Strength Here

By Thomas Niel, InvestorPlace Contributor

Yet, that's not to say it's smooth sailing ahead for GNOG and LCA stock. Limited runway, and increased igaming competition, could sink shares as well. Add in a deal that may benefit a billionaire more so than rank-and-file shareholders, and it's clear selling into the recent strength is the way to go. And those who haven't bought in yet? Wait for a pullback before buying.

5 Gun Stocks to Watch for Investors With a Steady Hand

By Thomas Niel, InvestorPlace Contributor

Civil unrest, the pandemic and the U.S. presidential election have made these five gun stocks winning plays this year.

Load More